Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

neurodegenerative disorders

- PMLiVE

Ventyx’s investigational NLRP3 inhibitor shows promise in Parkinson’s disease

Planning is currently underway for a placebo-controlled trial of the candidate

- PMLiVE

Roche to advance Parkinson’s disease candidate into phase 3 development

More than ten million people worldwide are living with the neurodegenerative disorder

- PMLiVE

UKDRI researchers to evaluate new blood test for neurodegenerative disease diagnosis

It is hoped that the test could be available for widespread UK use in the coming years

- PMLiVE

FDA grants RMAT designation to AskBio’s Parkinson’s gene therapy candidate

The progressive neurodegenerative disease affects more than ten million people worldwide

- PMLiVE

International Alzheimer’s disease prevention trial in at-risk young adults begins

The study will evaluate whether the amyloid beta protein can be blocked from ever accumulating in the brain

- PMLiVE

FDA approves Supernus Pharmaceuticals’ Onapgo to treat advanced Parkinson’s disease

The neurodegenerative disorder affects almost one million people in the US

- PMLiVE

AbbVie’s Parkinson’s disease candidate tavapadon shows promise in phase 3 trial

More than ten million people worldwide are living with the neurodegenerative disorder

- PMLiVE

UCB shares ‘encouraging’ data for Alzheimer’s disease candidate bepranemab

The drug showed benefits across key secondary endpoints, including tau accumulation

- PMLiVE

AbbVie’s continuous Parkinson’s disease therapy Vyalev approved by FDA

More than ten million people worldwide are living with the neurological disorder

- PMLiVE

AbbVie shares promising late-stage results for Parkinson’s disease candidate tavapadon

Approximately 153,000 people in the UK are currently living with the neurodegenerative disorder

- PMLiVE

Study reveals inflammation caused by infections could contribute to MS progression

The progressive, neurodegenerative disease is estimated to affect more than 130,000 people in the UK

Biogen Idec building

Biogen receives EC approval for Skyclarys in Friedreich’s ataxia patients

The company gained access to the drug through its $7.3bn acquisition of Reata Pharmaceuticals

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links